- Home
- MODD vs ANL Comparison
MODD vs ANL Comparison
Compare MODD & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- ANL
- Stock Information
- Founded
- MODD 1998
- ANL 2004
- Country
- MODD United States
- ANL Cayman Islands
- Employees
- MODD N/A
- ANL N/A
- Industry
- MODD Industrial Specialties
- ANL
- Sector
- MODD Health Care
- ANL
- Exchange
- MODD Nasdaq
- ANL Nasdaq
- Market Cap
- MODD 72.6M
- ANL 72.7M
- IPO Year
- MODD N/A
- ANL 2023
- Fundamental
- Price
- MODD $2.14
- ANL $3.16
- Analyst Decision
- MODD Buy
- ANL Strong Buy
- Analyst Count
- MODD 1
- ANL 2
- Target Price
- MODD $5.00
- ANL $9.00
- AVG Volume (30 Days)
- MODD 93.3K
- ANL 27.1K
- Earning Date
- MODD 11-19-2024
- ANL 08-08-2024
- Dividend Yield
- MODD N/A
- ANL N/A
- EPS Growth
- MODD N/A
- ANL N/A
- EPS
- MODD N/A
- ANL N/A
- Revenue
- MODD N/A
- ANL $5,000,000.00
- Revenue This Year
- MODD N/A
- ANL N/A
- Revenue Next Year
- MODD $830.43
- ANL N/A
- P/E Ratio
- MODD N/A
- ANL N/A
- Revenue Growth
- MODD N/A
- ANL N/A
- 52 Week Low
- MODD $1.00
- ANL $1.85
- 52 Week High
- MODD $2.65
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- MODD 43.50
- ANL 66.74
- Support Level
- MODD $2.15
- ANL $2.00
- Resistance Level
- MODD $2.34
- ANL $3.89
- Average True Range (ATR)
- MODD 0.11
- ANL 0.38
- MACD
- MODD -0.01
- ANL 0.14
- Stochastic Oscillator
- MODD 25.78
- ANL 61.74
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.